Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases

Journal of the American Academy of Dermatology

Volumn 58, Issue 5, 2008, Pages 750-754

  Boyd, Alan S ^a   Shakhtour, Bashar ^a   Shyr, Yu ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 2;

ARTICLE; BENIGN TUMOR; DYSPLASTIC NEVUS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MELANOCYTE; MELANOMA; NEVUS; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SKIN METASTASIS; TISSUE SECTION;

CELL CYCLE PROTEINS; DYSPLASTIC NEVUS SYNDROME; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOCYTES; MELANOMA; NEVUS; NUCLEAR PROTEINS; SKIN NEOPLASMS;

EID: 41949112898     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.12.026     Document Type: Article

References (27)

1. Freeman A., Morris L.S., Mills A.D., Stoeber K., Laskey R.A., Williams G.H., et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 5 (1999) 2121-2132
2. Rieger E., Hofmann-Wellenhof R., Soyer H.P., Kofler R., Cerroni L., Smolle J., et al. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. J Cutan Pathol 20 (1993) 229-236
3. Kuwata T., Kitagawa M., and Kasuga T. Proliferative activity of primary cutaneous melanocytic tumors. Virchows Arch A Pathol Anat 423 (1993) 359-364
4. Fogt F., Vortmeyer A.O., and Tahan S.R. Nucleolar organizer regions (AgNOR) and Ki-67 immunoreactivity in cutaneous melanocytic lesions. Am J Dermatopathol 17 (1995) 13-17
5. Ramsay J.A., From L., Iscoe N.A., and Kahn H.J. MIB-1 proliferative activity is significant prognostic factor in primary thick cutaneous melanoma. J Invest Dermatol 105 (1995) 22-26
6. Kanter L., Blegaen H., Wejde J., Lagerlof B., and Larsson O. Utility of a proliferation marker in distinguishing between benign nevocellular nevi and nevocellular nevus-like lesions with malignant properties. Melanoma Res 5 (1995) 345-350
7. Boni R., Doguoglu A., Burg G., Muller B., and Dummer R. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 35 (1996) 416-418
8. Sparrow L.E., English D.R., Taran J.M., and Heenan P.J. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol 20 (1998) 12-16
9. Niezabitowski A., Czajecki K., Rys J., Kruczak A., Gruchala A., Wasilewska A., et al. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70 (1999) 150-160
10. Li L.L., Crotty K.A., McCarthy S.W., Palmer A.A., and Kril J.J. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 22 (2000) 489-495
11. Bergman R., Malkin L., Sasbo E., and Kerner H. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol 44 (2001) 500-504
12. Alison M.R., Hunt T., and Forbes S.J. Minichromosome maintenance (MCH) proteins may be pre-cancer markers. Gut 50 (2002) 290-294
13. Korkolopoulou P., Givalos N., Saetta A., Goudopoulou A., Gakiopoulou H., Thymara I., et al. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Hum Pathol 36 (2005) 899-907
14. Blow J.J., and Dutta A. Preventing re-replication of chromosomal DNA. Nat Rev Cell Biol 6 (2005) 476-486
15. Maiorano D., Lutzmann M., and Mechali M. MCM proteins and DNA replication. Curr Opin Cell Biol 18 (2006) 132-136
16. Stoeber K., Halsall I., Freeman A., Swinn R., Doble A., Morris L., et al. Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine. Lancet 354 (1999) 1524-1525
17. Meng M.V., Grossfeld G.D., Williams G.H., Dilworth S., Stoeber K., Mulley T.W., et al. Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 7 (2001) 2712-2718
18. Ramnath N., Hernandez F.J., Dong-Feng T., Huberman J.A., Natarajan N., Beck A.F., et al. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 19 (2001) 4259-4266
19. Gonzalez M.A., Pinder S.E., Callagy G., Vowler S.L., Morris L.S., Bird K., et al. Minichromosome maintenance protein 2 is a strong independent marker in breast cancer. J Clin Oncol 21 (2003) 4306-4313
20. Scott I.S., Morris L.S., Bird K., Davies R.J., Vowler S.L., Rushbrook S.M., et al. A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. J Pathol 201 (2003) 187-197
21. Scott I.S., Odell E., Chatrath P., Morris L.S., Davies R.J., Vowler S.L., et al. A minimally invasive immunocytochemical approach to early detection of oral squamous cell carcinoma and dysplasia. Br J Cancer 94 (2006) 1170-1175
22. Kearsey S.E., and Labib K. MCM proteins: evolution, properties, and role in DNA replication. Biochim Biophys Acta 1398 (1998) 113-136
23. Tanaka T., Knapp D., and Nasmyth K. Loading of an Mcm protein onto DNA replication origins is regulated by Cdc6p and CDKs. Cell 90 (1997) 649-660
24. Williams G.H., Romanowski P., Morris L., Madine M., Mills A.D., Soeber K., et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci U S A 95 (1998) 14932-14937
25. Ha S.A., Shin S.M., Namkoong H., Lee H., Cho G.W., Hur S.Y., et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res 10 (2004) 8386-8395
26. Winnepenninckx V., Lazar V., Michiels S., Dessen P., Stas M., Alonso S.R., et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98 (2006) 472-482
27. Ilmonen S., Hernberg M., Pyrhonen S., Tarkkanen J., and Asko-Seljavaara S. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res 15 (2005) 375-381